Asset Details
Do you wish to reserve the book?
Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials
Do you wish to request the book?
Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials
2012
Overview
Background:
Pharmacological inhibitors of vascular endothelial growth factor (VEGF) receptors, like vatalanib, have been tested in randomised trials (CONFIRM (Colorectal Oral Novel therapy For the Inhibition of Angiogenesis and Retarding of Metastases) 1 and 2) in colorectal cancer showing activity in a subgroup of patients with high serum LDH expression. In the current study, we assessed the predictive role of vascular density (VD) in patients treated in the above trials.
Methods:
Paraffin-embedded materials from 141 patients were analysed with immunohistochemistry for the expression of the CD31 (pan-endothelial cell marker) and of phosphorylated pVEGFR2/KDR on endothelial cells. The VD was correlated with response to therapy and with progression-free (PFS) and overall survival (OS).
Results:
A significant association of pVEGFR2/KDR+ VD with poor response in the placebo group was noted (response rates (RRs) 15% (3/20) when high VD
vs
52% (26/50) when low VD;
P
=0.006). The RR increased from 15 (3/20) to 50% (11/22) in tumours with high VD when vatalanib was added to chemotherapy (
P
=0.02). A significantly improved PFS was noted in patients with high pVEGFR2/KDR+ VD when treated with vatalanib (
P
=0.002). A similar effect was also noted in patients with high CD31+ VD (
P
=0.07). Overall survival was marginally improved (
P
=0.07).
Conclusion:
Assessment of the activated vessel density may allow the stratification of patients recruited in randomised trials with VEGFR-targeting anti-angiogenic agents, unmasking their therapeutic potential and enabling their introduction in the clinical practice for the benefit of specific patient subgroups, at the same time reducing the cost of therapy.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adult
/ Aged
/ Angiogenesis Inhibitors - therapeutic use
/ Biological and medical sciences
/ Biomedical and Life Sciences
/ Colorectal Neoplasms - blood supply
/ Colorectal Neoplasms - drug therapy
/ Colorectal Neoplasms - metabolism
/ Colorectal Neoplasms - pathology
/ Endothelial Cells - drug effects
/ Endothelial Cells - metabolism
/ Female
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Humans
/ Immunohistochemistry - methods
/ Male
/ Neovascularization, Pathologic - pathology
/ Oncology
/ Phthalazines - therapeutic use
/ Platelet Endothelial Cell Adhesion Molecule-1 - metabolism
/ Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
/ Tumors
/ Vascular endothelial growth factor
/ Vascular Endothelial Growth Factor Receptor-2 - metabolism
